

<

6 Financials of the Issuer

(INR mn)

Parameters	1st FY (March 31, 2026) ⁽¹⁾	2nd FY (March 31, 2027) ⁽¹⁾	3rd FY (March 31, 2028) ⁽¹⁾
Revenue from operations	21,243.3	N.A.	N.A.
Net Profit	5,917.9	N.A.	N.A.
Paid up Equity Share Capital	1,123.4	N.A.	N.A.
Reserves excluding revaluation reserves	29,301.7	N.A.	N.A.

*Note: (1) Will be updated in due course***7 Trading Status**

Company's Equity Shares are listed on both the BSE Limited and the NSE. The Shares have not been suspended or delisted.

Particulars	Status
(i) Current Status	Active
(ii) at the end of 1st FY (March 31, 2026)	Active
(iii) at the end of 2nd FY (March 31, 2027)	N.A.
(iv) at the end of 3rd FY (March 31, 2028)	N.A.

*Note: Trading status has not been disclosed since the relevant financial years have not been completed***8 Change in Directors of issuer from the disclosures in the offer document**

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2026) ⁽¹⁾	Ravikant Uppla; Ravindra Chandrappa	Re-Appointed
(ii) at the end of 2nd FY (March 31, 2027) ⁽¹⁾	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2028) ⁽¹⁾	N.A.	N.A.

*Note: (1) Will be updated in due course***9 Status of implementation of project/ commencement of commercial production**

(i) As disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

Particulars	Total estimated Fund requirement
(i) As disclosed in the offer document (Net Proceeds)	N.A.
(ii) Actual utilization (INR mn)	N.A.
(iii) Reasons for deviation, if any	N.A.

11 Comments of monitoring agency, if applicable

- (a) Comments on use of funds NA
(b) Comments on deviations, if any, in the use of N.A.
(c) Any other reservations expressed by the monitoring N.A.

Note: (1) Monitoring agency to issue the report at the end of the 1st Quarter immediately after the listing of the issue

12 Pricing Data

Issue Price (Rs.)	570.0
Designated Stock Exchange:	BSE
Listing Date:	21-Jul-25

Price parameters	At close of listing day (July 21, 2025)	Close of 30th calendar day from listing day (August 19, 2025)	Close of 90th calendar day from listing day (October 18, 2025)	At the end of FY 2026 ⁽¹⁾			At the end of FY 2027 ⁽²⁾			At the end of FY 2028 ⁽²⁾		
				Closing price	High	Low	Closing price	High	Low	Closing price	High	Low
Market Price (BSE)	730.4	818.2	757.4	656.3	873.3	579.5	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
BSE SENSEX	82,200.3	81,644.4	83,952.2	71,947.6	86,159.0	71,425.0	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Note: (1) High / Low denotes intraday High / Low for the entire period.

(2) Will be updated in due course.

Source: BSE website

13 Basis for Issue Price

Accounting ratio	Name of Company	As disclosed in the offer document	At the end of 1st FY (FY 2026)	At the end of 2nd FY (FY 2027)	At the end of 3rd FY (FY 2028)
EPS (Diluted)(Rs.)	Issuer:	8.0	10.4	N.A.	N.A.
	Peers Average	28.5	31.4	N.A.	N.A.
	Syngene International	12.3	7.9	N.A.	N.A.
	Sai Life Sciences	8.6	16.4	N.A.	N.A.
	Cohance Lifesciences	10.5	4.7	N.A.	N.A.
	Div's Laboratories	82.5	96.8	N.A.	N.A.
P/E	Issuer:⁽¹⁾	70.9	62.9	N.A.	N.A.
	Peers Average	81.1	58.7	N.A.	N.A.
	Syngene International	51.5	49.6	N.A.	N.A.
	Sai Life Sciences	92.2	59.1	N.A.	N.A.
	Cohance Lifesciences	97.3	64.5	N.A.	N.A.
	Div's Laboratories	83.2	61.5	N.A.	N.A.
NAV per Equity Share	Issuer:	43.1	54.2	N.A.	N.A.
	Peers Average	214.2	242.7	N.A.	N.A.
	Syngene International	117.4	120.1	N.A.	N.A.
	Sai Life Sciences	102.1	117.3	N.A.	N.A.
	Cohance Lifesciences	72.3	102.2	N.A.	N.A.
	Div's Laboratories	564.9	631.4	N.A.	N.A.
RoNW (%)	Issuer:	20.8%	19.5%	N.A.	N.A.
	Peers Average	12.7%	9.9%	N.A.	N.A.
	Syngene International	11.1%	6.5%	N.A.	N.A.
	Sai Life Sciences	11.0%	14.0%	N.A.	N.A.
	Cohance Lifesciences	13.6%	3.8%	N.A.	N.A.
	Div's Laboratories	15.4%	15.3%	N.A.	N.A.

Sourced from Prospectus dated July 16, 2025

Note: (1) At Offer Price

14 Any other material information

Particulars	Date	Remarks
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited	8-Sep-25	
Intimation of violation under Company s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons as required under SEBI (Prohibition of Insider Trading) Regulations 2015 (SEBI PIT Regulations)	28-Oct-25	
Company reported violation under Company's Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons as required under SEBI (Prohibition of Insider Trading) Regulations 2015 ("SEBI PIT Regulations")	11-Nov-25	
The Board have approved allotment of 1,03,800 Equity Shares of face value of Rs. 2 (Rupees two only) each to the eligible employees of the Company upon exercise of the Options vested with them under the Anthem Employee Stock Option Plan 2024.	5-Feb-26	
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2025, the Company has executed on February 23, 2026, First amendment to the Loan agreement dated April 15, 2024, entered with Neoantherm Lifesciences Private Limited (Wholly Owned Subsidiary)	23-Feb-26	
Company informed the exchange of the resignation of Mr. K Ramakrishnan from the position of General Counsel and consequently from the role of Senior Management Personnel of the Company with effect from March 31, 2026.	13-Feb-26	
The Board have approved the appointment of M/s. S.R. Batliboi & Associates LLP as the Statutory Auditors of the Company at its Meeting held on April 22, 2026, subject to the approval of the Shareholders.	22-Apr-26	

DISCLAIMER:

The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the "Circular") for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance.

The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited (www.bseindia.com), The National Stock Exchange of India Limited (www.nseindia.com), websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as "www.capitalmarkets.com" and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise.

The information disclosed on this website is updated as of May 27, 2026. Citi does not undertake to update the information contained herein except as required by applicable law or regulation.